Matthew Cinal Bombard, DO
Clinical Assistant Professor, Department of Emergency Medicine
1000 Oakland Drive
Kalamazoo, MI 49008
Matthew Bombard, DO, FAAEM, is a board certified emergency medicine physician with American Physician Partners in Kalamazoo, Michigan. He is a graduate of Central Michigan University, Mount Pleasant, Michigan, and received a Bachelor of Science in Neurology and Psychology. He earned his medical degree from Michigan State University College of Osteopathic Medicine, East Lansing, Michigan. He completed a residency in Emergency Medicine at Henry Ford Macomb Hospital and was Chief of his program his final year. He completed a Leadership and Advocacy Fellowship with the Virginia College of Emergency Medicine. He was formerly a clinical instructor in Osteopathic Medical Specialties at Michigan State University College of Osteopathic Medicine. He has been heavily involved with physician advocacy with both the Michigan Osteopathic Association and Virginia College of Emergency Physicians. His clinical, teaching, and research interests include medical education, physician advocacy, and patient satisfaction.
Education and Training
- Co-Chief Resident 2018, Emergency Medicine Education Chief, Henry Ford Health System
- Residency 2017, Emergency Medicine, Henry Ford Health System
- DO 2014, Michigan State University
- BS 2008, Neuroscience and Psychiatry, Central Michigan University
- Patient Satisfaction
- Medical Education
Rossignol J., Fink K., Crane A., Davis K., Bombard M., Clerc S., Bavar A., Lowrance S., Song C., Witte S., Lescaudron L., Dunbar G. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number Stem Cell Research and Therapy. 2015;6(1) doi: 10.1186/scrt545.
Rossignol J., Fink K., Davis K., Clerc S., Crane A., Matchynski J., Lowrance S., Bombard M., Dekorver N., Lescaudron L., Dunbar G. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of huntington's disease Stem Cells. 2014;32(2):500-509. doi: 10.1002/stem.1508.
Fink K., Rossignol J., Crane A., Davis K., Bombard M., Bavar A., Clerc S., Lowrance S., Song C., Lescaudron L., Dunbar G. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: Behavioral and neuropathological analysis Stem Cell Research and Therapy. 2013;4(5) doi: 10.1186/scrt341.
Dey N., Bombard M., Roland B., Davidson S., Lu M., Rossignol J., Sandstrom M., Skeel R., Lescaudron L., Dunbar G. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease Behavioural Brain Research. 2010;214(2):193-200. doi: 10.1016/j.bbr.2010.05.023.
Shear D., Lu X., Bombard M., Pedersen R., Chen Z., Davis A., Tortella F. Longitudinal characterization of motor and cognitive deficits in a model of penetrating ballistic-like brain injury Journal of Neurotrauma. 2010;27(10):1911-1923. doi: 10.1089/neu.2010.1399.
Dey N., Boersen A., Myers R., York L., Bombard M., Lu M., Sandstrom M., Hulce V., Lescaudron L., Dunbar G. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease Restorative Neurology and Neuroscience. 2007;25(5-6):485-492.